Akademgorodok Plans To Launch A Smallpox Drug Into Production

Akademgorodok Plans To Launch A Smallpox Drug Into Production
Akademgorodok Plans To Launch A Smallpox Drug Into Production

Video: Akademgorodok Plans To Launch A Smallpox Drug Into Production

Video: Akademgorodok Plans To Launch A Smallpox Drug Into Production
Video: Can Smallpox Be Weaponised? 2023, April
Anonim

Scientists in Novosibirsk have completed clinical trials of a new drug for smallpox NIOCH-14, said on Friday at a meeting of women scientists with the Prime Minister of Russia

Image
Image

Mikhail Mishustin

Director of the Novosibirsk Institute of Organic Chemistry (NIOCh) named after N. N. Vorozhtsova

Elena Bagryanskaya

“We are launching NIOCH-14 into production, this is our drug against smallpox, which our scientists have created together with Vector, the clinic has already passed, and we intend to launch it,” she said. Wherein

Elena Bagryanskaya

noted that in order to start production, the institute needs to reconstruct its own facilities.

Smallpox drug NIOCH-14 is a joint development of the State Research Center for Virology and Biotechnology "Vector" and NIOCH. At the moment, there is not a single domestic chemical preparation for the treatment and emergency prevention of smallpox and other orthopoxvirus diseases in humans.

The Food and Drug Administration (FDA) in July 2018 registered the first and only drug to date for the treatment of smallpox - Tecovirimat (TPOXX).

About the disease

Smallpox is an acute highly contagious human infectious disease caused by the Variola virus (Latin Variola), which is resistant to low temperatures and drying.

It was possible to cope with the disease thanks to the WHO global vaccination program, which has been implemented since the second half of the 1960s. The last human case of smallpox was recorded on October 26, 1977 in Somalia. The victory over the disease was officially announced in 1980. Smallpox is the first and only human infectious disease that has been eradicated worldwide as a result of a vaccination campaign.

Only two laboratories have the right to store the virus and conduct research: the Russian Center for Virology and Biotechnology "Vector" (Koltsovo, Novosibirsk region) and the American Center for Disease Control and Prevention (Atlanta, Georgia).

Popular by topic